Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Chronic Pancreatitis II: Collaborative Care

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:

Search research articles

Home
Research Domains
Biomedical And Clinical Sciences
Oncology And Carcinogenesis
Predictive And Prognostic Markers
Predictive And Prognostic Factors Of Efficacy Of Third-line Chemotherapy In Patients With Unresectable Pancreatic Cancer: A Cohort-based Study.

Home
Research Domains
Biomedical And Clinical Sciences
Oncology And Carcinogenesis
Predictive And Prognostic Markers
Predictive And Prognostic Factors Of Efficacy Of Third-line Chemotherapy In Patients With Unresectable Pancreatic Cancer: A Cohort-based Study.

Related Experiment Video

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

Predictive and prognostic factors of efficacy of third-line chemotherapy in patients with unresectable pancreatic cancer: a cohort-based study.

Camille Evrard^1,2, Antoine Pelras³, Simon Rivet⁴

¹Medical Oncology Department, Poitiers University Hospital, Poitiers 86000, France.

|June 14, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

Predicting the efficacy of third-line chemotherapy for advanced pancreatic cancer is crucial. Patient and tumor characteristics effectively predict survival, aiding treatment decisions for advanced pancreatic ductal adenocarcinoma (aPDAC).

Keywords:

cohort pancreatic cancer predictive factors third-line chemotherapy

More Related Videos

An Orthotopic Resectional Mouse Model of Pancreatic Cancer

An Orthotopic Resectional Mouse Model of Pancreatic Cancer

Published on: September 24, 2020

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

Related Experiment Videos

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

An Orthotopic Resectional Mouse Model of Pancreatic Cancer

An Orthotopic Resectional Mouse Model of Pancreatic Cancer

Published on: September 24, 2020

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

Area of Science:

Oncology
Clinical Medicine
Cancer Research

Background:

Advanced pancreatic ductal adenocarcinoma (aPDAC) presents a poor prognosis, with a median overall survival (OS) of approximately 12 months.
Identifying predictors of third-line chemotherapy (L3) efficacy is vital for patient selection in this controversial treatment setting.

Purpose of the Study:

To identify factors predicting progression-free survival (PFS) and OS in patients with aPDAC receiving L3 chemotherapy.
To develop a model for predicting L3 chemotherapy benefit in aPDAC.

Main Methods:

A multicenter retrospective cohort study involving 202 French patients with aPDAC who received at least three treatment lines.
Penalized Cox regressions were employed to analyze PFS and OS in patients undergoing L3 chemotherapy.

Main Results:

Median PFS was 2.2 months and median OS was 4.2 months for L3 chemotherapy.
Key predictors for both PFS and OS included age, sex, prior surgery, first-line FOLFIRINOX, treatment durations, ECOG-PS, metastasis (peritoneum, liver, lung), and resource depletion.
The predictive model demonstrated acceptable discrimination for 6-month survival outcomes (AUC 0.83 for PFS, 0.73 for OS).

Conclusions:

Readily available clinical characteristics of patients and their aPDAC can predict survival outcomes with L3 chemotherapy.
An online calculator based on these factors can assist physicians in determining the potential benefit of L3 chemotherapy.